Inhibition of interleukin 2 signaling and signal transducer and activator of transcription (STAT)5 activation during T cell receptor-mediated feedback inhibition of T cell expansion

Journal of Experimental Medicine

Volumn 190, Issue 9, 1999, Pages 1263-1274

  Lee, In Hong ^a,d   Li, Wai Ping ^a   Hisert, Katherine B ^b   Ivashkiv, Lionel B ^a,c  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Cornell/Rockefeller/Sloan K ^*  (United States)

^c Weill Cornell Medical Center   (United States)

^d Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

Cytokines; Gene activation; Inhibition; Mitogen activated protein kinases; Signal transduction

Indexed keywords

FAS ANTIGEN; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANTIBODIES; ANTIGENS, CD3; APOPTOSIS; CELL DIVISION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; INTERLEUKIN-2; JANUS KINASE 1; JANUS KINASE 3; LYMPHOCYTE ACTIVATION; MILK PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANTIGEN, T-CELL; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANS-ACTIVATORS; TRANSFECTION;

EID: 0345281581     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.9.1263     Document Type: Article

References (66)

1. Kotzin, B.L., D.Y. Leung, J. Kappler, and P. Marrack. 1993. Superantigens and their potential role in human disease. Adv. Immunol. 54:99-166.
2. Oxenius, A., R.M. Zinkernagel, and H. Hengartner. 1998. Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. Immunity. 9:449-457.
3. Van Parijs, L., and A.K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 280:243-248.
4. Kuroda, K., J. Yagi, K. Imanishi, X.J. Van, X.Y. Li, W. Fujimaki, H. Kato, T. Miyoshi-Akiyama, Y. Kumazawa, H. Abe, and T. Uchiyama. 1996. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial super-antigen. J. Immunol. 157:1422-1431.
5. Vella, A.T., S. Dow, T.A. Potter, J. Kappler, and P. Marrack. 1998. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 95:3810-3815.
6. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521-530.
7. Akbar, A.N., and M. Salmon. 1997. Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Immunol. Today. 18:72-76.
8. Ashwell, J.D., R.E. Cunningham, P.D. Noguchi, and D. Hernandez. 1987. Cell growth cycle block of T cell hybridomas upon activation with antigen. J. Exp. Med. 165:173-184.
9. Matis, L.A., L.H. Glimcher, W.E. Paul, and R.H. Schwartz. 1983. Magnitude of response of histocompatibility-restricted T-cell clones is a function of the product of the concentrations of antigen and Ia molecules. Proc. Natl. Acad. Sci. USA. 80:6019-6023.
10. Miyatake, S., H. Nakano, S.Y. Park, T. Yamazaki, K. Takase, H. Matsushime, A. Kato, and T. Saito. 1995. Induction of G1 arrest by down-regulation of cyclin D3 in T cell hybridomas. J. Exp. Med. 182:401-408.
11. Nau, G.J., R.L. Moldwin, D.W. Lancki, D.K. Kim, and F.W. Fitch. 1987. Inhibition of IL-2 driven proliferation of murine T lymphocyte clones by supraoptimal levels of immobilized anti-T cell receptor monoclonal antibody. J. Immunol. 139:114-122.
12. Suzuki, G., Y. Kawase, S. Koyasu, I. Yahara, Y. Kobayashi, and R.H. Schwartz. 1988. Antigen-induced suppression of the proliferative response of T cell clones. J. Immunol. 140: 1359-1365.
13. Russell, J.H., C.L. White, D.Y. Loh, and P. Meleedy-Rey. 1991. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc. Natl. Acad. Sci. USA. 88:2151-2155.
14. Wang, J., and M.J. Lenardo. 1997. Molecules involved in cell death and peripheral tolerance. Curr. Opin. Immunol. 9:818-825.
15. Lissy, N.A., L.F. Van Dyk, M. Becker-Hapak, A. Vocero-Akbani, J.H. Mendler, and S.F. Dowdy. 1998. TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point. Immunity. 8:57-65.
16. Boehme, S.A., and M.J. Lenardo. 1993. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. Immunol. 23:1552-1560.
17. Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:441-444.
18. Dhein, J., H. Walczak, C. Baumler, K.M. Debatin, and P.H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/ (Fas/CD95). Nature. 373:438-441.
19. Ju, ST., D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D.H. Sherr, B.Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:444-448.
20. Refaeli, Y., L. Van Parijs, C.A. London, J. Tschopp, and A.K. Abbas. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 8:615-623.
21. Zheng, L., C.L. Trageser, D.M. Willerford, and M.J. Lenardo. 1998. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J. Immunol. 160:763-769.
22. Smith, K.A. 1988. Interleukin-2: inception, impact, and implications. Science. 240:1169-1176.
23. Radvanyi, L.G., G.B. Mills, and R.G. Miller. 1993. Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death. J. Immunol. 150:5704-5715.
24. Su, B., and M. Karin. 1996. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr. Opin. Immunol. 8:402-411.
25. Qian, D., and A. Weiss. 1997. T cell antigen receptor signal transduction. Curr. Opin. Cell Biol. 9:205-212.
26. Lin, A.W., M. Barradas, J.C. Stone, L. van Aelst, M. Serrano, and S.W. Lowe. 1998. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12:3008-3019.
27. Qui, M.S., and S.H. Green. 1992. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. Neuron. 9:705-717.
28. Sengupta, T.K., E.M. Schmitt, and L.B. Ivashkiv. 1996. Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Proc. Natl. Acad. Sci. USA. 93:9499-9504.
29. Sengupta, T.K., E.S. Talbot, P.A. Scherle, and L.B. Ivashkiv. 1998. Rapid inhibition of interleukin-6 signaling and stat3 activation mediated by mitogen-activated protein kinases. Proc. Natl. Acad. Sci. USA. 95:11107-11112.
30. Wong, B., J. Arron, and Y. Choi. 1997. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis. J. Exp. Med. 186:1939-1944.
31. Ivashkiv, L.B., E.M. Schmitt, and A. Castro. 1996. Inhibition of transcription factor Stat1 activity in mononuclear cell cultures and T cells by the cyclic AMP signaling pathway. J. Immunol. 157:1415-1421.
32. Brennan, P., J.W. Babbage, B.M. Burgering, B. Groner, K. Reif, and D.A. Cantrell. 1997. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity. 7:679-689.
33. Castro, A., T.K. Sengupta, D.C. Ruiz, E. Yang, and L.B. Ivashkiv. 1999. IL-4 selectively inhibits IL-2-triggered stat5 activation, but not proliferation, in human T cells. J. Immunol. 162:1261-1269.
34. Beadling, C., K.W. Johnson, and K.A. Smith. 1993. Isolation of interleukin 2-induced immediate-early genes. Proc. Natl. Acad. Sci. USA. 90:2719-2723.
35. Karnitz, L.M., and R.T. Abraham. 1996. Interleukin-2 receptor signaling mechanisms. Adv. Immunol. 61:147-199.
36. Taniguchi, T., and Y. Minami. 1993. The IL-2/IL-2 receptor system: a current overview. Cell. 73:5-8.
37. Gaffen, S.L., M.A. Goldsmith, and W.C. Greene. 1998. Interleukin-2 and the interleukin-2 receptor. In The Cytokine Handbook. Academic Press, Inc., San Diego. 73-103.
38. Leonard, W.J., and J.J. O'Shea. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293-322.
39. Iezzi, G., K. Karjalainen, and A. Lanzavecchia. 1998. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 8:89-95.
40. Welte, T., D. Leitenberg, B.N. Dittel, B.K. al-Ramadi, B. Xie, Y.E. Chin, CA. Janeway, Jr., A.L.M. Bothwell, K. Bottomly, and X.Y. Fu. 1999. STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation. Science. 283:222-225.
41. Ahmed, N.N., H.L. Grimes, A. Bellacosa, T.O. Chan, and P.N. Tsichlis. 1997. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc. Natl. Acad. Sci. USA. 94:3627-3632.
42. Loetscher, P., M. Seitz, M. Baggiolini, and B. Moser. 1996. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 184:569-577.
43. Matsumoto, A., M. Masuhara, K. Mitsui, M. Yokouchi, M. Ohtsubo, H. Misawa, A. Miyajima, and A. Yoshimura. 1997. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 89: 3148-3154.
44. Firpo, E.J., A. Koff, M.J. Solomon, and J.M. Roberts. 1994. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell Biol. 14: 4889-4901.
45. Turner, J.M. 1993. IL-2-dependent induction of G1 cyclins in primary T cells is not blocked by rapamycin or cyclosporin A. Int. Immunol. 5:1199-1209.
46. Drappa, J., A.K. Vaishnaw, K.E. Sullivan, J.L. Chu, and K.B. Elkon. 1996. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335:1643-1649.
47. Fisher, G.H., F.J. Rosenberg, S.E. Straus, J.K. Dale, L.A. Middleton, A.Y. Lin, W. Strober, M.J. Lenardo, and J.M. Puck. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:935-946.
48. Rieux-Laucat, F., F. Le Deist, C. Hivroz, I.A. Roberts, K.M. Debatin, A. Fischer, and J.P. de Villartay. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1347-1349.
49. DeSilva, D.R., E.A. Jones, M.F. Favata, B.D. Jaffee, R.L. Magolda, J.M. Trzaskos, and P.A. Scherle. 1998. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J. Immunol. 160:4175-4181.
50. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell. 81:323-330.
51. Moriggl, R., D.J. Topham, S. Teglund, V. Sexl, C. McKay, D. Wang, A. Hoffmeyer, J. van Deursen, M.Y. Sangster, K.D. Bunting, et al. 1999. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 10: 249-259.
52. Teglund, S., C. McKay, E. Schuetz, J.M. van Deursen, D. Stravopodis, D. Wang, M. Brown, S. Bodner, G. Grosveld, and J.N. Ihle. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:841-850.
53. Nakajima, H., X.W. Liu, A. Wynshaw-Boris, L.A. Rosenthal, K. Imada, D.S. Finbloom, L. Hennighausen, and W.J. Leonard. 1997. An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for StatSa in IL-2-mediated IL-2 receptor alpha chain induction. Immunity. 7:691-701.
54. Modiano, J.F., J. Domenico, A. Szepesi, J.J. Lucas, and E.W. Gelfand. 1994. Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells. J. Biol. Chem. 269:32972-32978.
55. Beadling, C., D. Guschin, B.A. Witthuhn, A. Ziemiecki, J.N. Ihle, I.M. Kerr, and D.A. Cantrell. 1994. Activation of JAK kinases and STAT proteins by interleukin-2 and Interferon alpha, but not the T cell antigen receptor, in human T lymphocytes. EMBO (Eur. Mol. Biol. Organ.) J. 13:5605-5615.
56. Azam, M., C. Lee, I. Strehlow, and C. Schindler. 1997. Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity. 6:691-701.
57. Kim, T.K., and T. Maniatis. 1996. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science. 273:1717-1719.
58. Haspel, R.L., M. Salditt-Georgieff, and J.E. Darnell, Jr. 1996. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO (Eur. Mol. Biol. Organ.) J. 15:6262-6268.
59. Shuai, K., J. Liao, and M.M. Song. 1996. Enhancement of antiproliferative activity of gamma interferon by the specific inhibition of tyrosine dephosphorylation of Stat1. Mol. Cell Biol. 16:4932-4941.
60. Aragane, Y., D. Kulms, T.A. Luger, and T. Schwarz. 1997. Down-regulation of interferon gamma-activated STAT1 by UV light. Proc. Natl. Acad. Sci. USA. 94:11490-11495.
61. Chung, C.D., J. Liao, B. Liu, X. Rao, P. Jay, P. Berta, and K. Shuai. 1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 278:1803-1805.
62. Endo, T.A., M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misawa, et al. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 387:921-924.
63. Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, et al. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature. 387:924-929.
64. Starr, R., T.A. Willson, E.M. Viney, L.J. Murray, J.R. Rayner, B.J. Jenkins, T.J. Gonda, W.S. Alexander, D. Metcalf, N.A. Nicola, and D.J. Hilton. 1997. A family of cytokine-inducible inhibitors of signalling. Nature. 387:917-921.
65. Feldman, G.M., E.J. Chuang, and D.S. Finbloom. 1995. IgG immune complexes inhibit IFN-gamma-induced transcription of the Fc gamma RI gene in human monocytes by preventing the tyrosine phosphorylation of the p91 (Stat1) transcription factor. J. Immunol. 154:318-325.
66. Marth, T., and B.L. Kelsall. 1997. Regulation of interleukin-12 by complement receptor 3 signaling. J. Exp. Med. 185: 1987-1995.